Company / Current Liabilities
Solid Biosciences Inc. Current Liabilities History
FY2018-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Current Liabilities
$22.5M
FY2022
5-year range
$12.5M / $24.5M
FY2018-FY2022
Trend
-4.6%
vs FY2021
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $24M to $23M over the past 2 years.
Based on SEC 10-K filings.
$23M in FY2022 with a 3-year CAGR of +7.2%.
Improved from $24M to $23M over the past 2 years.
Current Liabilities over time
Growth rates
- 3-Year CAGR
- +7.2%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of +7.2%, indicating consistent growth.
- In FY2022, current liabilities decreased 4.6% year-over-year.
- Peak current liabilities was recorded in FY2020.
- Lowest current liabilities in the period was in FY2018.
Company context
Key Data Points
- Altman Z-Score 1.22 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Current LiabilitiesValue | YoY GrowthYoY |
|---|---|---|
| FY2022 | $22.5M | -4.6% |
| FY2021 | $23.6M | -3.6% |
| FY2020 | $24.5M | +33.9% |
| FY2019 | $18.3M | +46.4% |
| FY2018 | $12.5M | - |
As of FY2022 · SEC 10-K · Updated Jun 28, 2026